TIDMSNG
Synairgen plc
06 January 2022
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces global strategic partnership with Ashfield
Engage
Southampton, UK - 6 January 2022: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001 (inhaled interferon-beta or
IFN-beta) for the treatment of COVID-19 as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered
directly into the lungs, today announces a partnership with global
experts in strategic engagement and commercialisation, Ashfield
Engage.
Leveraging its COVID-19 experience, Ashfield Engage is
supporting Synairgen as it builds its commercialisation
infrastructure for the needs of SNG001, initially in the US,
pending completion of pivotal trials and regulatory authorisations.
This will include the recruitment of dedicated medical affairs,
patient services, commercial and market access teams.
SNG001 is an investigational inhaled formulation of the
naturally occurring antiviral protein IFN-beta for potential use in
patients hospitalised with COVID-19. The SARS-CoV-2 virus supresses
local production of IFN-beta prevents induction of anti-viral
responses by infected cells.
"There remains an urgent need for new therapies to treat
hospitalised COVID-19 patients in order to prevent disease
progression, accelerate hospital discharge and enable patients to
quickly resume their usual activities, " said Richard Hennings,
Chief Commercial Officer of Synairgen. "We are excited to be
working with Ashfield Engage given their relevant COVID-19
experience and are confident they understand our needs and values
as we build the optimal team."
In November 2021, Synairgen announced that it had completed
enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and
expects top-line data early this year. SNG001 has also recently
graduated to the Phase 3 part of the US National Institute of
Health's ACTIV-2 trial.
Greg Flynn, Global President of Ashfield Engage , said: "It is a
privilege to support Synairgen in bringing this innovative
potential treatment to COVID-19 patients. Having initially
collaborated with Synairgen regarding patient support, we have
together developed a truly consultative approach - taking the time
to fully understand patient needs and providing solutions in both
hospital and home settings.
"We're grateful that our collaboration has now evolved into a
significantly wider partnership which will see us recruiting
experts to support delivery of this novel nebulised antiviral to
patients, providing MSLs to educate on the SNG001 treatment, and
establishing medical information services to respond to patient
enquiries."
SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was
classified as an Urgent Public Health study by the UK's National
Institute for Health Research (NIHR).
No financial terms have been disclosed regarding the partnership
with Ashfield Engage.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Brooke.Clarke@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. SNG001 has been granted Fast Track status from the US Food
and Drug Administration (FDA) and the Phase 3 SPRINTER trial was
deemed an Urgent Public Health study by the UK's National Institute
for Health Research (NIHR). Synairgen's Phase 3 clinical programme
is currently evaluating SNG001 in patients across 17 countries. In
a Phase 2 trial in hospitalised COVID-19 patients, SNG001
demonstrated a greater than two-fold chance of recovery to 'no
limitation of activities' versus placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
(1)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
About Ashfield Engage
Ashfield Engage is an expert, global partner in customer
strategy and execution. Ashfield Engage helps clients to connect
with all healthcare audiences to ensure people get knowledge,
support and medicines when and where they need them. As experts in
strategic engagement, Ashfield Engage creates personalised,
impactful experiences for all healthcare audiences, across all
channels. Every programme is underpinned by human connections,
omnichannel engagement and adaptive analytics.
Ashfield Engage has over 20 years' experience with a team of
over 5,000 employees, delivering services in more than 50
countries. Offering services across Medical Affairs, Commercial,
Patient Solutions and Event Experiences, Ashfield Engage helps its
clients to engage with their stakeholders across the whole
commercialisation journey.
For more information, visit www.ashfieldengage.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAFFKEANAEFA
(END) Dow Jones Newswires
January 06, 2022 06:59 ET (11:59 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024